CinCor Pharma, Inc. (NASDAQ:CINC) Expected to Announce Earnings of -$0.50 Per Share

Wall Street analysts forecast that CinCor Pharma, Inc. (NASDAQ:CINCGet Rating) will post earnings of ($0.50) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for CinCor Pharma’s earnings. The highest EPS estimate is ($0.43) and the lowest is ($0.55). The company is scheduled to issue its next earnings results on Monday, January 1st.

On average, analysts expect that CinCor Pharma will report full-year earnings of ($2.28) per share for the current fiscal year, with EPS estimates ranging from ($2.52) to ($1.95). For the next financial year, analysts forecast that the business will report earnings of ($2.97) per share, with EPS estimates ranging from ($3.44) to ($2.66). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow CinCor Pharma.

CinCor Pharma (NASDAQ:CINCGet Rating) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.50) EPS for the quarter, meeting analysts’ consensus estimates of ($0.50).

Shares of NASDAQ:CINC opened at $15.33 on Friday. CinCor Pharma has a 52 week low of $13.00 and a 52 week high of $30.66. The firm has a fifty day simple moving average of $19.82.

A number of hedge funds have recently bought and sold shares of CINC. UBS Group AG purchased a new stake in CinCor Pharma during the first quarter valued at about $38,000. California State Teachers Retirement System purchased a new stake in CinCor Pharma during the first quarter valued at about $87,000. JPMorgan Chase & Co. acquired a new position in shares of CinCor Pharma during the first quarter worth about $95,000. American International Group Inc. acquired a new position in shares of CinCor Pharma during the first quarter worth about $101,000. Finally, MetLife Investment Management LLC acquired a new position in shares of CinCor Pharma during the first quarter worth about $142,000. 52.53% of the stock is owned by hedge funds and other institutional investors.

CinCor Pharma Company Profile (Get Rating)

CinCor Pharma, Inc, a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases.

See Also

Get a free copy of the Zacks research report on CinCor Pharma (CINC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CinCor Pharma (NASDAQ:CINC)

Want More Great Investing Ideas?

Receive News & Ratings for CinCor Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CinCor Pharma and related companies with MarketBeat.com's FREE daily email newsletter.